Article
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Oncotarget - 4 Oct 2016
Lou Na-Na, Zhang Xu-Chao, Chen Hua-Jun, Zhou Qing, Yan Li-Xu, Xie Zhi, Su Jian, Chen Zhi-Hong, Tu Hai-Yan, Yan Hong-Hong, Wang Zhen, Xu Chong-Rui, Jiang Ben-Yuan, Wang Bin-Chao, Bai Xiao-Yan, Zhong Wen-Zhao, Wu Yi-Long, Yang Jin-Ji
Abstract excerpt
The co-occurrence of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular subtype of non-small-cell lung cancer (NSCLC). Herein, we assessed the clinical outcomes and incidence of acquired resistance to tyrosine kinase inhibitors (TKIs) in this subtype. So we enrolled 118 advanced NSCLC treated with TKIs. EGFR mutations and ALK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.